June 17, 2020
Article
Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.
An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.
The drug also reduced the risk of myocardial infarction and stroke.
Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.
Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.
Todd Hobbs, MD, breaks down research presented at ADA 2020.
June 16, 2020
Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.
Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.
The prevention of type 2 diabetes is possible and has important clinical benefits.
Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.